On April 30, 2026 , the FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B bulks list entirely, saying there is no clinical need for large-scale compounding
R Ochratoxin A competes for glucuronidation
The Peptide Compliance Crisis In October 2023, the FDA issued warning letters to multiple peptide providers for marketing non-approved peptides as research chemicals while clearly selling them for human use
Factors That Deplete Your Natural Levels Age is the most consistent factor in glutathione decline, but it isn't the only one
BPC-157 and GHK-Cu are research peptides that the FDA has indicated cannot legally be marketed as dietary supplement ingredients
Growth, carcass composition and plasma melatonin in postpubertal beef heifers fed [PMID: 3366708] Laboratory literature summary: Growth, carcass composition and plasma melatonin in postpubertal beef heifers fed melatonin